NCT06540105
Leveraging Artificial Intelligence and Multi-Omics Data to Predict Opioid Addiction
Active, Not Recruiting
Not specifiedAges 18+ObservationalUniversity of California, San DiegoInvestigator-initiated
~300 participants
Updated 2026-07-07 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
opioid use disorder at baseline based on the DSM-5 criteria
Measured over baseline
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Rodney A Gabriel, MD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
diagnosis of OUD (active or in remission) defined by the DSM-5 criteria
age ≥ 18 years old
Exclusion
inability to participate independently with the study (i.e. dementia)
chronic opioid use that is not consistent with a diagnosis of OUD
patients that are pregnant
children
institutionalized individuals
non-English speaking subjects as there are several surveys without appropriate translation and with sensitive information (e.g., questions about mental health and history of drug use) that is required to complete the study.
What this trial measures
- opioid use disorder at baseline based on the DSM-5 criteriabaseline
risk of opioid use disorder based on genomics, social determinants of health, microbiome, and other clinical data. Patients with OUD will be enrolled and compared to healthy controls using data from external datasets such as NIH All of Us Research Program. Diagnosis of opioid use disorder will be based on the DSM-5 criteria for opioid use disorder